Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Organovo Holdings, Inc. operates as a biology company. The Company focuses on bio-printing technology and creating tissues for research and medical applications.



Growth: Good revenue growth rate 100.0%, there is acceleration compared to average historical growth rates -16.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -400.0%. On average the margin is improving steadily. Gross margin is low, 0.0%.

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 200.6% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 14.4% higher than minimum and 89.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -17.1x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ONVO
Share price, USD:  (+2.0%)1.03
year average price 1.4105  


year start price 2.1900 2023-03-31

max close price 2.2400 2023-04-10

min close price 0.9000 2024-02-09

current price 1.0300 2024-03-29
Common stocks: 8 713 617

Dividend Yield:  0.0%
Last revenue growth (y/y):  > 200.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  -16.7%
Historical growth of EBITDA:  0.0%
EV / Sales: -8.5x
Margin (EBITDA LTM / Revenue): -400.0%
Fundamental value created in LTM:
Market Cap ($m): 9
Net Debt ($m): -26
EV (Enterprise Value): -17
Price to Book: 1.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-09-08GlobeNewsWire

Organovo to Participate in the H.C. Wainwright Global Investment Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ONVO ONVO ONVO ONVO ONVO ONVO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-08 2023-11-09 2023-08-10 2023-07-14 2023-02-09 2022-11-10
acceptedDate 2024-02-08 16:05:34 2023-11-09 17:10:34 2023-08-10 16:07:13 2023-07-13 19:24:11 2023-02-09 16:06:23 2022-11-10 16:07:45
calendarYear 2023.000 2023.000 2023.000 2022.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 5000.000 0 75 000 162 000 131 000 77 000
costOfRevenue 72 000 70 000 0 0 0 0
grossProfit -67 000 -70 000 75 000 162 000 131 000 77 000
grossProfitRatio -13.400 0 1.000 1.000 1.000 1.000
researchAndDevelopmentExpenses 1M 1M 2M 5M 1M 1M
generalAndAdministrativeExpenses 2M 3M 3M 2M 2M 2M
sellingAndMarketingExpenses 14 000 13 000 0 -85 000 85 000 0
sellingGeneralAndAdministrativeExpenses 2M 3M 3M 2M 2M 2M
otherExpenses 0 0 0 14 000 85 000 15 000
operatingExpenses 4M 4M 4M 8M 3M 3M
costAndExpenses 4M 4M 4M 8M 3M 3M
interestIncome 76 000 121 000 157 000 177 000 143 000 103 000
interestExpense 0 0 0 -320 000 -95 000 103 000
depreciationAndAmortization 72 000 71 000 67 000 -84 000 178 000 124 000
ebitda -4M -4M -4M -8M -3M -3M
ebitdaratio -736.000 0 -55.200 -48.537 -24.282 -41.948
operatingIncome -4M -4M -4M -8M -3M -3M
operatingIncomeRatio -736.000 0 -55.933 -48.019 -25.641 -43.558
totalOtherIncomeExpensesNet 76 000 121 000 12 000 320 000 95 000 33 000
incomeBeforeTax -4M -4M -4M -7M -3M -3M
incomeBeforeTaxRatio -720.800 0 -53.680 -46.043 -24.916 -43.130
incomeTaxExpense -72 000 -71 000 2000.000 -463 000 -95 000 -103 000
netIncome -4M -4M -4M -7M -3M -3M
netIncomeRatio -720.800 0 -53.707 -43.185 -24.191 -41.792
eps -0.400 -0.460 -0.460 -0.800 -0.360 -0.370
epsdiluted -0.400 -0.460 -0.460 -0.800 -0.360 -0.370
weightedAverageShsOut 9M 9M 9M 9M 9M 9M
weightedAverageShsOutDil 9M 9M 9M 9M 9M 9M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ONVO ONVO ONVO ONVO ONVO ONVO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-08 2023-11-09 2023-08-10 2023-07-14 2023-02-09 2022-11-10
acceptedDate 2024-02-08 16:05:34 2023-11-09 17:10:34 2023-08-10 16:07:13 2023-07-13 19:24:11 2023-02-09 16:06:23 2022-11-10 16:07:45
calendarYear 2023.000 2023.000 2023.000 2022.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 5M 8M 11M 15M 20M 13M
shortTermInvestments 0 0 0 706 000 554 000 11M
cashAndShortTermInvestments 5M 8M 11M 16M 21M 24M
netReceivables 33 000 55 000 149 000 152 000 76 000 0
inventory 0 0 0 0 0 0
otherCurrentAssets 913 000 624 000 792 000 889 000 788 000 519 000
totalCurrentAssets 6M 8M 12M 17M 22M 24M
propertyPlantEquipmentNet 2M 2M 2M 3M 3M 3M
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 143 000 143 000 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 355 000 409 000 605 000 658 000 920 000 837 000
totalNonCurrentAssets 3M 3M 3M 3M 3M 4M
otherAssets 0 0 0 0 0 0
totalAssets 9M 11M 15M 20M 25M 28M
accountPayables 471 000 435 000 488 000 331 000 242 000 441 000
shortTermDebt 502 000 499 000 495 000 492 000 488 000 486 000
taxPayables 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0
otherCurrentLiabilities 727 000 666 000 787 000 3M 646 000 462 000
totalCurrentLiabilities 2M 2M 2M 4M 1M 1M
longTermDebt 999 000 1M 1M 1M 1M 2M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities -1.000 0 0 0 0 0
totalNonCurrentLiabilities 998 999 1M 1M 1M 1M 2M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 999 000 2M 2M 2M 2M 2M
totalLiabilities 3M 3M 3M 5M 3M 3M
preferredStock 0 0 0 0 0 0
commonStock 10000.000 9000.000 9000.000 9000.000 9000.000 9000.000
retainedEarnings -337M -333M -329M -325M -318M -314M
accumulatedOtherComprehensiveIncomeLoss 1000.000 1000.000 2000.000 2000.000 3000.000 0
othertotalStockholdersEquity 343M 341M 341M 340M 340M 339M
totalStockholdersEquity 6M 8M 12M 15M 22M 25M
totalEquity 6M 8M 12M 15M 22M 25M
totalLiabilitiesAndStockholdersEquity 9M 11M 15M 20M 25M 28M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 9M 11M 15M 20M 25M 28M
totalInvestments 143 000 143 000 0 706 000 554 000 11M
totalDebt 2M 2M 2M 2M 2M 2M
netDebt -4M -6M -9M -13M -18M -11M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ONVO ONVO ONVO ONVO ONVO ONVO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-08 2023-11-09 2023-08-10 2023-07-14 2023-02-09 2022-11-10
acceptedDate 2024-02-08 16:05:34 2023-11-09 17:10:34 2023-08-10 16:07:13 2023-07-13 19:24:11 2023-02-09 16:06:23 2022-11-10 16:07:45
calendarYear 2023.000 2023.000 2023.000 2022.000 2023.000 2023.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -4M -4M -4M -7M -3M -3M
depreciationAndAmortization 72 000 71 000 67 000 59 000 130 000 54 000
deferredIncomeTax -243 000 0 -160 000 0 0 0
stockBasedCompensation 157 000 675 000 475 000 500 000 544 000 673 000
changeInWorkingCapital -121 000 142 000 -2M 2M -460 000 359 000
accountsReceivables 22 000 94 000 3000.000 -76 000 -76 000 0
inventory 0 0 -2M 2M 0 0
accountsPayables 36 000 -53 000 157 000 25 000 -199 000 311 000
otherWorkingCapital -179 000 101 000 -1000.000 1000.000 -185 000 48 000
otherNonCashItems 217 000 -43 000 88 000 -144 000 6000.000 18 000
netCashProvidedByOperatingActivities -4M -3M -5M -5M -3M -2M
investmentsInPropertyPlantAndEquipment 0 -27 000 -15 000 -162 000 -41 000 -119 000
acquisitionsNet 0 -58 000 -718 000 0 0 0
purchasesOfInvestments -2M -3M -5M 10M -10M -335 000
salesMaturitiesOfInvestments 2M 2M 6M 368 000 10M 0
otherInvestingActivites 0 776 000 718 000 -10M 10M 368 000
netCashUsedForInvestingActivites 27 000 12 000 764 000 -162 000 10M -86 000
debtRepayment 0 0 0 0 0 0
commonStockIssued 1M 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 0 0 0 0 0 0
netCashUsedProvidedByFinancingActivities 1M 0 0 0 0 0
effectOfForexChangesOnCash 2M 0 0 0 0 0
netChangeInCash -2M -3M -5M -5M 7M -2M
cashAtEndOfPeriod 5M 8M 11M 15M 20M 13M
cashAtBeginningOfPeriod 8M 11M 15M 20M 13M 16M
operatingCashFlow -4M -3M -5M -5M -3M -2M
capitalExpenditure 0 -27 000 -15 000 -162 000 -41 000 -119 000
freeCashFlow -4M -3M -5M -5M -3M -2M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-01-25 13:05 ET
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
2024-01-09 13:05 ET
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
2023-12-06 13:05 ET
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
2023-11-08 13:05 ET
Organovo Highlights FXR314 Combination Therapy Potential and Plan
2023-09-08 16:46 ET
Organovo to Participate in the H.C. Wainwright Global Investment Conference
2023-08-23 12:05 ET
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
2023-03-21 12:05 ET
Organovo Announces FXR Program
2022-11-15 13:05 ET
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
2022-09-06 12:20 ET
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-09-06 12:05 ET
Organovo Announces Postponement of Annual Meeting of Stockholders
2022-05-17 12:05 ET
Organovo Achieves 3D Tissue Model for Crohn’s Disease
2022-03-01 13:05 ET
UPDATE -- Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
2022-02-23 13:05 ET
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
2022-02-23 13:05 ET
Organovo and BICO (CELLINK) Reach Licensing Agreement on Bioprinting Patents
2022-02-18 21:00 ET
Organovo Holdings, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-02-18 18:00 ET
Organovo Welcomes New Sr. Vice President of Strategy and Business Development
2022-02-02 17:00 ET
Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents
2022-02-02 17:00 ET
Organovo Guides on Patent Portfolio and Successful IPR Defense of Two Patents
2022-01-10 17:00 ET
Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk
2022-01-10 17:00 ET
Organovo Files Counterclaims In Patent Lawsuit Brought Against It by CellInk
2021-11-30 13:05 ET
Organovo On Track to Establish Human 3D Disease Model in Inflammatory Bowel Disease in 2022
2021-09-17 20:10 ET
Organovo Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum
2021-03-02 13:05 ET
Organovo Announces Participation at the H.C. Wainwright Global Life Sciences Conference March 9-10 2021 (VIRTUAL CONFERENCE)
2020-09-03 20:05 ET
Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement
2020-08-17 12:05 ET
Organovo Announces One-for-Twenty Reverse Stock Split
2020-04-07 20:12 ET
Organovo Announces Termination of Merger Agreement with Tarveda Therapeutics
2020-04-02 12:00 ET
Organovo Holdings Founder Calls on Board of Directors to Accept Stockholders’ Opposition to the Illogical Merger With Tarveda Therapeutics
2020-03-31 22:30 ET
Organovo Holdings, Inc. Reminds Stockholders About Adjourned Special Meeting of Stockholders
2020-03-31 19:25 ET
Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt
2020-03-27 20:05 ET
Organovo Holdings, Inc. Announces Adjournment of Special Meeting of Stockholders
2020-03-23 19:30 ET
Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders
2020-03-19 18:36 ET
Organovo Founder Issues Letter to Stockholders Regarding Major Missteps and Misjudgment of the Company’s Board of Directors
2020-02-26 13:30 ET
Organovo Files Definitive Proxy Statement and Sends Letter to Stockholders
2019-12-16 12:00 ET
Organovo and Tarveda Therapeutics Announce Definitive Merger Agreement
2019-10-02 23:31 ET
Organovo Acknowledges Receipt of Proposal

SEC forms

Show financial reports only

SEC form 10
2024-02-08 16:05 ET
Organovo reported for 2023 q4
SEC form 10
2024-02-08 00:00 ET
Organovo reported for 2023 q4
SEC form 10
2023-11-09 17:10 ET
Organovo reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Organovo reported for 2023 q3
SEC form 6
2023-08-22 16:45 ET
Organovo published news for 2023 q2
SEC form 10
2023-08-10 16:07 ET
Organovo reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Organovo reported for 2023 q2
SEC form 6
2023-07-31 16:05 ET
Organovo published news for 2023 q2
SEC form 6
2023-07-24 16:27 ET
Organovo published news for 2023 q2
SEC form 6
2023-07-14 17:05 ET
Organovo published news for 2023 q2
SEC form 10
2023-07-13 19:24 ET
Organovo reported for 2023 q1
SEC form 6
2023-06-29 16:06 ET
Organovo published news for 2023 q1
SEC form 6
2023-03-15 17:14 ET
Organovo published news for 2022 q4
SEC form 10
2023-02-09 16:06 ET
Organovo reported for 2022 q4
SEC form 10
2023-02-09 00:00 ET
Organovo reported for 2022 q4
SEC form 10
2022-11-10 16:07 ET
Organovo reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Organovo reported for 2022 q3
SEC form 6
2022-10-14 16:07 ET
Organovo published news for 2022 q3
SEC form 6
2022-09-06 08:06 ET
Organovo published news for 2022 q2
SEC form 10
2022-08-11 16:22 ET
Organovo reported for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Organovo reported for 2022 q2
SEC form 6
2022-07-26 17:06 ET
Organovo published news for 2022 q2
SEC form 10
2022-06-10 16:16 ET
Organovo reported for 2022 q1
SEC form 10
2022-06-10 00:00 ET
Organovo reported for 2022 q1
SEC form 6
2022-03-10 16:30 ET
Organovo published news for 2021 q4
SEC form 6
2022-03-10 16:05 ET
Organovo published news for 2021 q4
SEC form 6
2022-02-28 16:07 ET
Organovo published news for 2021 q4
SEC form 10
2022-02-14 16:06 ET
Organovo published news for 2021 q4
SEC form 10
2022-02-14 00:00 ET
Organovo published news for 2021 q4
SEC form 6
2021-11-19 16:05 ET
Organovo published news for 2021 q3
SEC form 10
2021-11-08 16:08 ET
Organovo published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Organovo published news for 2021 q3
SEC form 6
2021-11-01 21:50 ET
Organovo published news for 2021 q3
SEC form 6
2021-10-06 16:47 ET
Organovo published news for 2021 q3
SEC form 6
2021-10-01 16:05 ET
Organovo published news for 2021 q3
SEC form 6
2021-09-17 16:13 ET
Organovo published news for 2021 q2
SEC form 10
2021-08-06 16:06 ET
Organovo published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Organovo published news for 2021 q2
SEC form 6
2021-08-05 17:01 ET
Organovo published news for 2021 q2
SEC form 6
2021-07-29 17:01 ET
Organovo published news for 2021 q2
SEC form 10
2021-06-15 16:06 ET
Organovo published news for 2021 q1
SEC form 10
2021-06-15 00:00 ET
Organovo published news for 2021 q1
SEC form 6
2021-05-13 16:05 ET
Organovo published news for 2021 q1
SEC form 6
2021-04-19 16:05 ET
Organovo published news for 2021 q1
SEC form 6
2021-03-10 16:08 ET
Organovo published news for 2020 q4
SEC form 10
2021-02-08 16:05 ET
Organovo published news for 2020 q4
SEC form 6
2020-12-31 16:05 ET
Organovo published news for 2020 q3
SEC form 6
2020-11-25 17:25 ET
Organovo published news for 2020 q3
SEC form 10
2020-11-05 16:11 ET
Organovo published news for 2020 q3